Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.5012 +0.0012 (+0.24%)
Streaming Delayed Price Updated: 10:59 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
Via Benzinga
Topics Stocks
9 Analysts Have This To Say About Sangamo Therapeutics
Via Benzinga
Stocks Lower Midday As 2024 Comes To An End
Stocks are lower midday, as Wall Street heads for its second consecutive winning year. 
Via Talk Markets
Topics Stocks / Equities
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet
Via Benzinga
US Stocks Open Higher; House Prices Increase In October
Via Benzinga
The Analyst Landscape: 6 Takes On Sangamo Therapeutics
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Sangamo Therapeutics's Earnings Outlook
Via Benzinga
4 Analysts Have This To Say About Sangamo Therapeutics
Via Benzinga
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results. 
Via Benzinga
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
Via Benzinga
Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?
Sangamo Therapeutics stock is heading higher on Tuesday as SGMO investors react to a new $50 million license agreement. 
Via InvestorPlace
US Stocks Poised To Open Higher On Last Trading Day Of 2024: Analyst Sees S&P 500 At 7,000 In First Half Of 2025
U.S. stock futures were trading higher on Tuesday following Monday's selloff. All four index futures rose in trade. 
Via Benzinga
Topics Stocks
CompoSecure, Cemtrex And 3 Stocks To Watch Heading Into Tuesday
U.S. stock futures down, investors eye EHang, Sangamo, Cemtrex, CompoSecure, Ambow. Check out Benzinga's premarket coverage & top tech stocks to watch. 
Via Benzinga
US Stocks Likely To Open Higher After Plunging On Powell's Hawkish Comments: Analyst Calls It A 'Healthy' Reaction From An 'Overly Optimistic' Market
U.S. stock futures climbed on Thursday in premarket hours after a hawkish cut from the Federal Reserve on Wednesday. 
Via Benzinga
Topics Economy
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Zeta Global, Spirit Airlines And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
Via Benzinga
What's Going On With Sangamo Therapeutics Shares Tuesday?
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an accelerated pathway for ST-920, a potential gene therapy for the treatment of... 
Via Benzinga
Crude Oil Rises Sharply; 3M Posts Upbeat Earnings
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Falls Over 150 Points; General Motors Tops Q3 Views
Via Benzinga
Topics Stocks
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly treatment reduces bleeding rates and offers convenience via an... 
Via Benzinga
Why Sangamo Therapeutics Stock Is Soaring
Sangamo Therapeutics shares are trading higher Tuesday after the company announced it has entered into a license agreement with Genentech to develop intravenously administered genomic medicines for... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.